WXXWY News and Press, Wuxi Biologics Cayman Inc ADR From 03/22/23

2023-03-22 09:00:04 ET Wuxi Biologics ADR press release ( OTCPK:WXXWY ): FY Non-GAAP EPS of RMB1.13. Revenue of RMB15.27B (+48.4% Y/Y). For further details see: Wuxi Biologics ADR Non-GAAP EPS of RMB1.13, revenue of RMB15.27B

Summary WuXi Biologics revenue growth slowed sharply to 48.4% last year, but it got a jumpstart with its signing of a major new order last month. The company's major shareholder recently sold 56 million shares, the latest in a steady series of such sales since its listing in 2017. I...

Summary WuXi Biologics outlicensed global rights for up to four pre-clinical bi- and multi-specific TCE antibodies to GSK in a $1.5 billion agreement. ArriVent Biopharma of Philadelphia is raising another $145 million to bring drugs from China and other emerging biotech hubs to the US m...

China-based WuXi Biologics ( OTCPK:WXXWY ) ( OTCPK:WXIBF ) announced an agreement with GSK ( NYSE: GSK ) on Thursday under which the U.K. pharma giant will obtain exclusive licenses for up to four T cell engaging (TCE) antibodies. The deal covers one preclinical bi-specific TC...

WuXi Biologics and GSK Enter into License Agreement on Multiple Novel Bi- & Multi-specific T Cell Engagers WuXi Biologics and GSK Enter into License Agreement on Multiple Novel Bi- & Multi-specific T Cell Engagers PR Newswire WuXi Biologics will provide an exclusiv...

WuXi Biologics (Shanghai) Co., Ltd. Removed from the U.S. Commerce Department's Unverified List PR Newswire SHANGHAI , Dec. 15, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio", 2269.HK), a leading global Contract Research, Development and Manufacturing Organizati...

WuXi Biologics Launches an Integrated Biologics CRDMO Center in Fengxian, Shanghai PR Newswire SHANGHAI , Nov. 21, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organizat...

Summary China pharma company Jinxi Jemincare out-licensed global rights for its androgen receptor degrader to Roche in a $650 million agreement. The oral small-molecule candidate, developed in Jemincare’s R&D center, is currently in preclinical testing. Shanghai IASO Bi...

WuXi Biologics ( OTCPK:WXXWY ) ( OTCPK:WXIBF ) and Toregem BioPharma tentatively formed a strategic partnership to develop monoclonal antibody TRG035 for treating congenital adentia (CA). CA is a genetic disorder characterized by complete or partial...

WuXi Biologics and Toregem BioPharma Sign MOU for Development of Anti-USAG-1 Antibody PR Newswire SHANGHAI , Oct. 11, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organi...